Drugs / Allogeneic hMSCs
Allogeneic hMSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02013674 | Feb 2014 → Mar 2017 | myocardial infarction, myocardial ischemia | Joshua M Hare | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01392625 Comparator | May 2011 → Aug 2016 | dilated cardiomyopathy | Joshua M Hare | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic hMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02013674 ↗ |
| Known as | Allo-hMSCs | “Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections...” NCT01392625 ↗ |
| Known as | allogeneic mesenchymal stem cells | “Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized...” PMID 25354998 ↗ Oct 2014 |
| Modality | Cell therapy | “Allogeneic Adult Human Mesenchymal Stem Cells (MSCs)” NCT02013674 ↗ |
| Route | Other | “Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection” NCT02013674 ↗ |